Clinical trial
Vidaza to Restore Hormone Thx Prostate
NCT00384839 · US Oncology Research, Industry · Completed
Key facts
| NCT number | NCT00384839 |
|---|---|
| Title | Vidaza to Restore Hormone Thx Prostate |
| Official title | Phase II Study for the Use of Vidaza™ to Restore Responsiveness of Patients' Prostate Cancers to Hormonal Therapy |
| Lead sponsor | US Oncology Research, Industry |
| Collaborators | Celgene Corporation Industry University of Southern California |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | azacitidine for injectable suspension |
| Enrollment | 36 |
| Start date | Apr 1, 2006 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Oct 6, 2006 |
| Last update posted | Oct 25, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: